US Edition
8 Articles
8 Articles
See how Sweden contributed to the new EU pharmaceutical legislation
After two years of negotiations, EU Member States have reached an agreement on revised pharmaceutical legislation. This process faced significant challenges, particularly regarding data protection and incentives for developing priority antimicrobials. “We are pleased that negotiations have been successful and that the countries have joined our position on maintaining data protection. This is a great success for Sweden and patients in the EU. We …
Launching a new pharma product in Europe: 6 supply chain cost factors to consider
Successfully launching a pharmaceutical product in Europe requires navigating a complex array of commercial, regulatory, and operational considerations. While strategic and regulatory topics are often well-covered, a new report from AIM zeroes in on a narrower, yet critical aspect: the cost of setting up and operationalizing a European supply chain.
The Act establishing the State Agency for Public Health (Aesap) is at the end of its procedure and the various parliamentary groups have already submitted their amendments to the aforementioned regulation. Among the independent and regionalist parties, some have decided to sign with the Government and have preferred to do so alone. This is the case of UPN, Junts and BNG, which have focused their proposals on strengthening the role of pharmacies,…
The new rules are intended to increase the availability of medicines and strengthen the competitiveness of the EU pharmaceutical industry.
Coverage Details
Bias Distribution
- 100% of the sources lean Left
To view factuality data please Upgrade to Premium
